GentaGel-Ler

GentaGel-LR is an Israeli biotechnology company developing a local, slow-release antibiotic treatment designed to prevent and treat severe localized infections. The company's core technology, invented by Prof. Avi Domb, utilizes a biodegradable polymer hydrogel to deliver antibiotics (such as gentamicin) directly to the site of infection, maintaining high local therapeutic concentrations for up to 60 days while avoiding systemic side effects. GentaGel-LR's lead program is being evaluated for diabetic foot ulcers, bone infections, and surgical site infections, with a clinical pilot demonstrating promising results in preventing amputations. The company is currently advancing further clinical trials in Israel and the United States to support its regulatory pathway with the FDA.